olmesartan medoxomil has been researched along with Diabetes Mellitus, Type 2 in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 13 (61.90) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, TX; Ding, A; Li, ZL; Yang, H; Zhang, H; Zhang, HT; Zhu, WP; Zhu, Y | 1 |
| Asai, S; Kanou, N; Nakayama, T; Nishida, Y; Susa, N; Takahashi, Y | 1 |
| Chatzikyrkou, C; Haller, H; Menne, J; Ritz, E; Ruilope, LM; Viberti, G | 1 |
| Lee, J; Matsushima, N; Mendell, J; O'Reilly, TE | 1 |
| Chrysant, SG; Heyrman, R; Karki, S; Lee, J; Melino, M; Oparil, S | 1 |
| Kereiakes, DJ; Neutel, JM | 2 |
| Kereiakes, DJ; Neutel, J | 1 |
| Hirata, T; Horimai, C; Irie, J; Itoh, H; Kawai, T; Matsumoto, H; Saisho, Y; Shimada, A; Takei, I; Tanaka, K | 1 |
| Littlejohn, T; Neutel, JM; Qian, C; Ram, CV; Sachson, R; Shojaee, A; Stoakes, KA | 1 |
| Nandi, U; Pal, TK; Sengupta, P | 1 |
| Fujisawa, G; Iwazu, Y; Kimura, M; Kobayashi, E; Kobayashi, T; Kusano, E; Masuda, T; Murakami, T; Muto, S; Nonaka-Sarukawa, M; Sasaki, N; Shimada, K; Shinohara, M; Watanabe, Y | 1 |
| Maa, JF; Nesbitt, SD; Shojaee, A; Weir, MR | 1 |
| Inagi, R; Ishikawa, N; Koike, H; Kurokawa, K; Miyata, T; Mizuno, M; Nangaku, M; Sada, T; Ueda, Y; van Ypersele de Strihou, C; Yuzawa, H | 1 |
| Buchholz, K; Fliser, D; Haller, H | 1 |
| Abe, Y; Kimura, S; Kiyomoto, H; Kobori, H; Kohno, M; Miyata, K; Miyatake, A; Nagai, Y; Nishiyama, A; Ozawa, Y; Shokoji, T; Yao, L; Yukimura, T | 1 |
| Fliser, D; Haller, H; Loos, A; Tsikas, D; Wagner, KK | 1 |
| Bolbrinker, J; Huber, M; Kreutz, R | 1 |
| Fukushima, Y; Kato, M; Koike, H; Mizuno, M; Sada, T; Terashima, H | 1 |
| Harada, N; Nakaya, Y; Niwa, Y; Ohnaka, M; Sakamoto, S | 1 |
| Kato, M; Koike, H; Mizuno, M; Sada, T | 1 |
12 trial(s) available for olmesartan medoxomil and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Female; Follow-Up Studies; Humans; Imidazoles; Kidney; Logistic Models; Male; Middle Aged; Odds Ratio; Olmesartan Medoxomil; Proportional Hazards Models; Renin-Angiotensin System; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome | 2014 |
A thorough QTc study demonstrates that olmesartan medoxomil does not prolong the QTc interval.
Topics: Adolescent; Adult; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Electrocardiography; Female; Healthy Volunteers; Heart; Humans; Long QT Syndrome; Male; Middle Aged; Olmesartan Medoxomil; Young Adult | 2016 |
Long-term efficacy of a combination of amlodipine and olmesartan medoxomil ± hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trial.
Topics: Age Factors; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Middle Aged; Olmesartan Medoxomil; Placebo Effect; Racial Groups; Tetrazoles; Time Factors; Treatment Outcome; United States | 2010 |
An olmesartan medoxomil-based treatment algorithm is effective in achieving 24-hour BP control in patients with type 2 diabetes mellitus, regardless of age, race, sex, or severity of hypertension: subgroup analysis of the BENIFICIARY study.
Topics: Adult; Age Factors; Aged; Algorithms; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Prospective Studies; Sex Characteristics; Tetrazoles | 2010 |
Efficacy of an olmesartan medoxomil-based treatment algorithm in patients with hypertension and type 2 diabetes: analysis of diurnal blood pressure control as assessed by 24-hour ambulatory blood pressure monitoring.
Topics: Aged; Algorithms; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Placebos; Prospective Studies; Tetrazoles | 2010 |
Effects of olmesartan medoxomil, an angiotensin II type 1 receptor antagonist, on plasma concentration of B-type natriuretic peptide, in hypertensive patients with type 2 diabetes mellitus: a preliminary, observational, open-label study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Natriuretic Peptide, Brain; Olmesartan Medoxomil; Prospective Studies; Tetrazoles | 2011 |
Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles; Treatment Outcome | 2011 |
Seated cuff blood pressure-lowering efficacy of an olmesartan medoxomil-based treatment regimen in patients with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Euphoria; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Prospective Studies; Tetrazoles; Young Adult | 2011 |
Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study).
Topics: Adult; Aged; Algorithms; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Drug Combinations; Drug Substitution; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Prospective Studies; Sodium Chloride Symporter Inhibitors; Tetrazoles; Time Factors; Treatment Outcome | 2013 |
Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis; Biomarkers; C-Reactive Protein; Chemokine CCL2; Cholesterol; Comorbidity; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Imidazoles; Intercellular Adhesion Molecule-1; Interleukin-6; Lipids; Male; Middle Aged; Olmesartan Medoxomil; Pravastatin; Prospective Studies; Receptor, Angiotensin, Type 1; Tetrazoles; Treatment Outcome; Tumor Necrosis Factor-alpha; Vasculitis | 2004 |
Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diabetes Mellitus, Type 2; Dinoprost; Double-Blind Method; Drug Administration Schedule; Female; Humans; Imidazoles; Kidney; Male; Middle Aged; Olmesartan Medoxomil; Oxidative Stress; Renal Circulation; Renin; Tetrazoles; Vascular Resistance | 2005 |
Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers.
Topics: Adolescent; Adult; Antihypertensive Agents; Area Under Curve; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glyburide; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles | 2006 |
9 other study(ies) available for olmesartan medoxomil and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Olmesartan Medoxomil, An Angiotensin II-Receptor Blocker, Ameliorates Renal Injury In db/db Mice.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Creatinine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Male; Mice; Olmesartan Medoxomil | 2019 |
Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Imidazoles; Logistic Models; Losartan; Male; Middle Aged; Multivariate Analysis; Olmesartan Medoxomil; Retrospective Studies; Telmisartan; Tetrazoles; Treatment Outcome; Uric Acid; Valine; Valsartan | 2013 |
Development of safety profile evaluating pharmacokinetics, pharmacodynamics and toxicity of a combination of pioglitazone and olmesartan medoxomil in Wistar albino rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Area Under Curve; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Combinations; Female; Hypoglycemic Agents; Imidazoles; Male; Olmesartan Medoxomil; Pioglitazone; Rats; Rats, Wistar; Tetrazoles; Thiazolidinediones | 2012 |
Heart angiotensin II-induced cardiomyocyte hypertrophy suppresses coronary angiogenesis and progresses diabetic cardiomyopathy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Apoptosis; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Hypertrophy; Hypertrophy, Left Ventricular; Imidazoles; Male; Myocytes, Cardiac; Neovascularization, Physiologic; Olmesartan Medoxomil; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley; Tetrazoles; Thrombospondin 1; Vascular Endothelial Growth Factor A; Ventricular Dysfunction, Left | 2012 |
Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model.
Topics: Animals; Antihypertensive Agents; Arginine; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glycation End Products, Advanced; Hydralazine; Hypertension, Renal; Imidazoles; Immunohistochemistry; In Vitro Techniques; Kidney; Lipids; Lysine; Male; Olmesartan Medoxomil; Oxidation-Reduction; Proteinuria; Rats; Tetrazoles | 2003 |
Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Collagen; Connective Tissue Growth Factor; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Hydralazine; Imidazoles; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Male; NADPH Oxidases; Olmesartan Medoxomil; Prediabetic State; Rats; Rats, Inbred OLETF; Receptors, Angiotensin; Renin; Tetrazoles; Thiazepines; Thiobarbituric Acid Reactive Substances; Transforming Growth Factor beta | 2005 |
The effect of angiotensin II receptor blockade on an end-stage renal failure model of type 2 diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blood Urea Nitrogen; Body Weight; Chemokine CCL2; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Imidazoles; Immunohistochemistry; Kidney Failure, Chronic; Lipids; Male; Olmesartan Medoxomil; Proteinuria; Rats; Serum Albumin; Survival Rate; Systole; Tetrazoles | 2006 |
Cilnidipine improves insulin sensitivity in the Otsuka Long-Evans Tokushima fatty rat, a model of spontaneous NIDDM.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dihydropyridines; Glucose Tolerance Test; Imidazoles; Insulin; Insulin Resistance; Lipid Metabolism; Male; Olmesartan Medoxomil; Rats; Rats, Inbred OLETF; Tetrazoles; Time Factors | 1999 |
Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Cytoprotection; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Dose-Response Relationship, Drug; Imidazoles; Insulin; Kidney; Lipids; Male; Olmesartan Medoxomil; Proteinuria; Rats; Rats, Inbred Strains; Rats, Zucker; Receptor, Angiotensin, Type 1; Serum Albumin; Tetrazoles | 2002 |